Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 5 | 6 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 7 | 7 |
| 2009 | 2 | 10 | 12 |
| 2010 | 3 | 11 | 14 |
| 2011 | 1 | 18 | 19 |
| 2012 | 2 | 15 | 17 |
| 2013 | 2 | 20 | 22 |
| 2014 | 0 | 30 | 30 |
| 2015 | 0 | 29 | 29 |
| 2016 | 0 | 42 | 42 |
| 2017 | 2 | 40 | 42 |
| 2018 | 3 | 30 | 33 |
| 2019 | 2 | 41 | 43 |
| 2020 | 1 | 40 | 41 |
| 2021 | 5 | 30 | 35 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 22 | 24 |
| 2025 | 0 | 41 | 41 |
| 2026 | 0 | 11 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Mol Cancer Ther. 2026 May 04; 25(5):844-859.
-
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clin Cancer Res. 2026 Apr 15; 32(8):1454-1461.
-
LRRC15-CAR T Cells for the Treatment of Osteosarcoma. Clin Cancer Res. 2026 Apr 15; 32(8):1557-1573.
-
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Sci Adv. 2026 Apr 03; 12(14):eaec8684.
-
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. Cancer Res. 2026 Apr 02; 86(7):1707-1723.
-
The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. Oncotarget. 2026 Mar 27; 17(1):78-89.
-
MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models. BMC Cancer. 2026 Feb 14; 26(1).
-
Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth. Mol Cancer Ther. 2026 Feb 04; 25(2):257-271.
-
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Mol Ther. 2026 Apr 01; 34(4):2154-2174.
-
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. J Med Chem. 2026 Jan 22; 69(2):1119-1134.